Loss of Somatostatin Receptor Subtype 2 in Prostate Cancer Is Linked to an Aggressive Cancer Phenotype, High Tumor Cell Proliferation and Predicts Early Metastatic and Biochemical Relapse

@inproceedings{Hennigs2014LossOS,
  title={Loss of Somatostatin Receptor Subtype 2 in Prostate Cancer Is Linked to an Aggressive Cancer Phenotype, High Tumor Cell Proliferation and Predicts Early Metastatic and Biochemical Relapse},
  author={Jan K Hennigs and Julia Mueller and Matti Adam and Joshua Michael Spin and Emilia Riedel and Markus Graefen and Carsten Bokemeyer and Guido Sauter and Hartwig Huland and Thorsten Schlomm and Sarah J P Minner},
  booktitle={PloS one},
  year={2014}
}
Somatostatin receptor subtype 2 (SSTR2) is the most frequently expressed SSTR subtype in normal human tissues. SSTR2 expression is differentially regulated in various tumor types and therapeutic somatostatin analogs binding to SSTR2 are in clinical use. In prostate cancers highly contradictory results in terms of SSTR2 expression and its consequences have been published over the past years. The aim of this study was to clarify prevalence and clinical significance of SSTR2 expression in prostate… CONTINUE READING
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

Somatostatin and Its Receptor Family

  • Frontiers in Neuroendocrinology
  • 1999
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…